MIST
Price
$1.58
Change
-$0.06 (-3.64%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
140.19M
19 days until earnings call
NERV
Price
$1.99
Change
-$0.00 (-0.00%)
Updated
Jul 18, 04:44 PM (EDT)
Capitalization
13.92M
25 days until earnings call
Interact to see
Advertisement

MIST vs NERV

Header iconMIST vs NERV Comparison
Open Charts MIST vs NERVBanner chart's image
Milestone Pharmaceuticals
Price$1.58
Change-$0.06 (-3.64%)
Volume$1.02K
Capitalization140.19M
Minerva Neurosciences
Price$1.99
Change-$0.00 (-0.00%)
Volume$100
Capitalization13.92M
MIST vs NERV Comparison Chart in %
Loading...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MIST vs. NERV commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a Hold and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (MIST: $1.65 vs. NERV: $1.99)
Brand notoriety: MIST and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIST: 130% vs. NERV: 559%
Market capitalization -- MIST: $140.19M vs. NERV: $13.92M
MIST [@Biotechnology] is valued at $140.19M. NERV’s [@Biotechnology] market capitalization is $13.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIST’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • MIST’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than MIST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIST’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 5 bullish TA indicator(s).

  • MIST’s TA Score: 4 bullish, 5 bearish.
  • NERV’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NERV is a better buy in the short-term than MIST.

Price Growth

MIST (@Biotechnology) experienced а -35.55% price change this week, while NERV (@Biotechnology) price change was +21.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

MIST is expected to report earnings on Nov 12, 2025.

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIST($140M) has a higher market cap than NERV($13.9M). NERV YTD gains are higher at: -10.425 vs. MIST (-30.085). NERV has higher annual earnings (EBITDA): 8.58M vs. MIST (-48.18M). MIST has more cash in the bank: 56M vs. NERV (17.3M). NERV has less debt than MIST: NERV (0) vs MIST (55.6M). MIST (0) and NERV (0) have equivalent revenues.
MISTNERVMIST / NERV
Capitalization140M13.9M1,007%
EBITDA-48.18M8.58M-561%
Gain YTD-30.085-10.425289%
P/E RatioN/A2.43-
Revenue00-
Total Cash56M17.3M324%
Total Debt55.6M0-
FUNDAMENTALS RATINGS
MIST vs NERV: Fundamental Ratings
MIST
NERV
OUTLOOK RATING
1..100
577
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4247
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (40) in the Biotechnology industry is in the same range as MIST (54) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

NERV's SMR Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

MIST's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as NERV (47) in the Biotechnology industry. This means that MIST’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MISTNERV
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STIM3.830.23
+6.39%
Neuronetics
DCOM28.850.49
+1.73%
Dime Community Bancshares
IFF75.030.81
+1.09%
International Flavors & Fragrances
UNF177.830.21
+0.12%
Unifirst Corp
PWM0.40-0.01
-3.21%
Prestige Wealth